



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/651,651	08/30/2000	Michael Lassner	MTC 6718	1981

7590 12/16/2004
ROBERT E. HANSON
FULBRIGHT & JAWORSKI LLP
600 CONGRESS AVENUE
SUITE 2400
AUSTIN, TX 78701

EXAMINER

KALLIS, RUSSELL

ART UNIT	PAPER NUMBER
----------	--------------

1638

DATE MAILED: 12/16/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/651,651

Applicant(s)

LASSNER ET AL.

Examiner

Russell Kallis

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 September 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-120 is/are pending in the application.
- 4a) Of the above claim(s) See Continuation Sheet is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) See Continuation Sheet is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 8/30/2000 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 1/03/01; 6/29/01.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application (PTO-152)
- ☒ Other: sequence attachments 1&2.

Continuation of Disposition of Claims: Claims withdrawn from consideration are 3-4, 8-9, 12-21, 24-25, 27, 29, 31, 33, 35, 37, 39, 51-75, 79-81, 83, 85, 87, 89-106, 109-110, 112, 114, 116 and 118-120.

Continuation of Disposition of Claims: Claims rejected are 1-2,5-7,10-11,22-23,26,28,30,32,34,36,38,40-5076-78,82,84,86,88,107,108,111,113,115,117.

Art Unit: 1638

DETAILED ACTION***Election/Restrictions***

Applicant's election without traverse of Group I, Claims 1-2, 5-19, 26, 28, 30, 32, 34, 36, 38, 40-50, 76-78, 82, 84, 86, 88, 107-108, 111, 113, 115 and 117 in the reply filed on 9/20/2004 is acknowledged. Claims 22 and 23, drawn to a recombinant construct comprising a polynucleotide encoding a lecithin:cholesterol acyltransferase-like polypeptide were inadvertently omitted from Group I and will be examined with elected Group I and elected polynucleotide sequence SEQ ID NO: 4.

Claims 1-120 are pending. Claims 3-4, 8-9, 12-21, 24-25, 27, 29, 31, 33, 35, 37, 39, 51-75, 79-81, 83, 85, 87, 89-106, 109-110, 112, 114, 116 and 118-120 are withdrawn as being drawn to non-elected Groups II-VII or non-elected polynucleotide sequences other than SEQ ID NO: 4. Claims 1-2, 5-7, 10-11, 22-23, 26, 28, 30, 32, 34, 36, 38, 40-50, 76-78, 82, 84, 86, 88, 107-108, 111, 113, 115 and 117 are examined.

Drawings

The drawings are objected to because Figure 5 does not clearly distinguish control, napin LCAT1, or napin LCAT3 transformants from each other. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and

Art Unit: 1638

appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. The replacement sheet(s) should be labeled "Replacement Sheet" in the page header (as per 37 CFR 1.84(c)) so as not to obstruct any portion of the drawing figures. If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Specification

The disclosure is objected to because of the following informalities: On pages 3-8 of the specification, Applicant recites the formula $5'X-(R_1)_n-(R_2)_n-(R_3)_n-Y3'$, and defines R_2 as any nucleotide and then states that R_2 is a nucleotide sequence selected from a particular group. Further, Applicant does not indicate what is R_3 . Appropriate correction is required.

Claim Objections

Claims 5-7, 32, 40, 48, 78 and 113, are objected to because of the following informalities: Claims 5-7, 32, 40, 43 and 113 recite non-elected polynucleotide or polypeptide sequences and Claims 48 and 78 recite a dependency to a non-elected claim. Appropriate correction is required.

Sequence Rules

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth: in the Brief Description of the Drawings beginning on page 9 of the

Art Unit: 1638

specification does not reference the non-plant LCAT sequences and plant LCAT sequences using sequence identifiers and does not indicate which vectors contain which sequence identifiers.

§ 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications;

(d) Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.

Applicant must amend the claims, specification, and/or drawings to insert sequence identifiers.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-2, 5-7, 10-11, 22-23, 26, 28, 30, 32, 34, 36, 38, 40-50, 76-78, 82, 84, 86, 88, 107-108, 111, 113, 115 and 117 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant broadly claims an isolated nucleic acid sequence comprising a polynucleotide encoding a plant lecithin:cholesterol acyltransferase-like polypeptide or fragment thereof; an isolated polynucleotide having at least 70% sequence identity to SEQ ID NO: 4; an isolated polynucleotide having at least 10 nucleotides that hybridize under condition of unspecified stringency to SEQ ID NO: 4; an isolated polynucleotide encoding SEQ ID NO: 5 with at least

Art Unit: 1638

one conservative amino acid substitution; an isolated polynucleotide that hybridizes to SEQ ID NO: 4 under conditions of unspecified stringency and encodes a plant lecithin:cholesterol acyltransferase-like polypeptide; an isolated nucleic acid sequence consisting of a polynucleotide having the formula $5'X-(R_1)_n-(R_2)_n-(R_3)_n-Y3'$, a recombinant construct comprising a regulatory sequence operably linked to a sequence encoding a lecithin:cholesterol acyltransferase-like polypeptide and host cells, plants and progeny and seeds transformed therewith.

Applicant describes a polynucleotide from human of SEQ ID NO: 1 encoding a lecithin:cholesterol acyltransferase (i.e. LCAT); LCAT1, LCAT2, LCAT3 from *Arabidopsis* identified from GenBank accessions AC00457, AC003027, and AL024486 comprising polynucleotides of SEQ ID NO: 2, 4 and 6 encoding lecithin:cholesterol acyltransferase-like polypeptides of SEQ ID NO: 3, 5 and 7 respectively; and additional *Arabidopsis* LCAT-like sequences LCAT4, LCAT7 and LCAT8 comprising polynucleotides SEQ ID NO: 8, 10 and 11.

Applicant does not describe any other LCAT encoding sequence other than the polynucleotide encoding a human lecithin:cholesterol acyltransferase and the polynucleotides from *Arabidopsis* encoding lecithin:cholesterol acyltransferase-like polypeptide sequences.

The Federal Circuit has recently clarified the application of the written description requirement to inventions in the field of biotechnology. The court stated that, "A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to members of the genus, which features constitute a substantial portion of the genus." *See University of California v. Eli Lilly and Co.*, 119 F.3d 1559; 43 USPQ2d 1398, 1406 (Fed. Cir. 1997).

Art Unit: 1638

Applicants fail to describe a representative number of isolated polynucleotides encoding a lecithin:cholesterol acyltransferase-like polypeptide; isolated polynucleotides having at least 70% sequence identity to SEQ ID NO: 4; isolated polynucleotides having at least 10 nucleotides that hybridize under condition of unspecified stringency to SEQ ID NO: 4; isolated polynucleotides encoding SEQ ID NO: 5 with at least one conservative amino acid substitution; isolated polynucleotide that hybridizes to SEQ ID NO: 4 under conditions of unspecified stringency and encodes a plant lecithin:cholesterol acyltransferase-like polypeptide; or a recombinant construct comprising a regulatory sequence operably linked to a polynucleotide sequence encoding a lecithin:cholesterol acyltransferase-like polypeptide. Applicants only describe the human (SEQ ID NO: 1) and *Arabidopsis* lecithin:cholesterol acyltransferase-like polynucleotide sequences of SEQ ID NO: 2, 4, 6, 8, 10 and 11. Furthermore, Applicants fail to describe structural features common to members of the claimed genus of polynucleotides encoding a lecithin:cholesterol acyltransferase-like polynucleotide; that have at least 70% sequence identity to SEQ ID NO: 4, that encode a polypeptide having at least one conservative amino acid substitution into SEQ ID NO: 5, that hybridize to at least 10 nucleotides of SEQ ID NO: 4; that hybridize to SEQ ID NO: 4 and either encode a lecithin:cholesterol acyltransferase-like polypeptide; or recombinant vectors that comprise a polynucleotide encoding a lecithin:cholesterol acyltransferase-like polypeptide. Hence, Applicants fail to meet either prong of the two-prong test set forth by *Eli Lilly*. Furthermore, given the lack of description of the necessary elements essential for polynucleotides encoding a lecithin:cholesterol acyltransferase-like polypeptide, it remains unclear what features identify a lecithin:cholesterol acyltransferase-like polypeptide. Since the genus of polynucleotides encoding lecithin:cholesterol

Art Unit: 1638

acyltransferase-like polypeptides from plant or from other sources has not been described by specific structural features, the specification fails to provide an adequate written description to support the breadth of the claims.

Sequences that hybridize with SEQ ID NO: 4 and encode a LCAT-like polypeptide, or hybridize to at least 10 nucleotides of SEQ ID NO: 4, or are which are at least 70% complementary to SEQ ID NO: 4, encompass naturally occurring allelic variants, mutants of SEQ ID NO: 4, as well as sequences encoding proteins having no known LCAT activity or LCAT-like activity, of which Applicant is not in possession. Accordingly, the specification fails to provide an adequate written description to support the genus of polynucleotides that are at least 70% complementary to SEQ ID NO: 4, that hybridize to SEQ ID NO: 4 and encode a lecithin:cholesterol acyltransferase-like polypeptide, or polynucleotides that hybridize to at least 10 nucleotides of SEQ ID NO: 4 encompassed by the hybridization language or percent identity language as set forth in the claims. (See Written Description guidelines published in Federal Register/Vol. 66, No.4/Friday, January 5, 2001/Notices: p.1099-1111).

Claims 1-2, 5-7, 10-11, 22-23, 26, 28, 30, 32, 34, 36, 38, 40-50, 76-78, 82, 84, 86, 88, 107-108, 111, 113, 115 and 117 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated polynucleotide of SEQ ID NO: 4 encoding a plant lecithin:cholesterol acyltransferase-like polypeptide of SEQ ID NO: 5, recombinant vectors comprising SEQ ID NO: 4, and plants transformed therewith having increased oil content in transformed seeds, does not reasonably provide enablement for any non-exemplified polynucleotide from plants or non-plant sources encoding a lecithin:cholesterol acyltransferase-like polypeptide or fragment thereof; or for non-exemplified polynucleotides which are at least

Art Unit: 1638

70% complementary to SEQ ID NO: 4; or for non-exemplified polynucleotide sequences that hybridize to any unspecified portion of at least 10 nucleotides of SEQ ID NO: 4, or for non-exemplified polynucleotides that hybridize to SEQ ID NO: 4 encoding a lecithin:cholesterol acyltransferase-like polypeptide other than SEQ ID NO: 4; or plants transformed with any sequence encoding a lecithin:cholesterol acyltransferase-like polypeptide in sense or antisense orientation producing transformed seeds having an increase in sterol-esters, oil content or sterol content in transformed seeds, or for plants transformed with LCAT2 SEQ ID NO: 4 producing transformed seeds having increased sterol-ester or increased phytosterol content. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

The claimed invention is not supported by an enabling disclosure taking into account the *Wands* factors. *In re Wands*, 858/F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988). *In re Wands* lists a number of factors for determining whether or not undue experimentation would be required by one skilled in the art to make and/or use the invention. These factors are: the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples of the invention, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, and the breadth of the claim.

Applicant broadly claims an isolated nucleic acid sequence comprising a polynucleotide encoding a plant lecithin:cholesterol acyltransferase-like polypeptide or fragment thereof; an isolated polynucleotide having at least 70% sequence identity to SEQ ID NO: 4; an isolated polynucleotide having at least 10 nucleotides that hybridize under condition of unspecified

Art Unit: 1638

stringency to SEQ ID NO: 4; an isolated polynucleotide that hybridizes to SEQ ID NO: 4 under conditions of unspecified stringency and encodes a plant lecithin:cholesterol acyltransferase-like polypeptide; an isolated polynucleotide encoding SEQ ID NO: 5 with at least one conservative amino acid substitution; a recombinant construct comprising a regulatory operably linked to a sequence encoding a lecithin:cholesterol acyltransferase and host cells, plants and progeny and seeds transformed therewith.

Applicant teaches PCR amplification of LCAT1-4 (SEQ ID NO: 2, 4, 6 and 8) using specific primers (page 36-37 of specification); cloning of LCAT 1, 2, 3 and 4 (SEQ ID NO: 2, 4, 6 and 8) into expression and transformation vectors in sense and antisense orientation (pages 40-41 of specification); transformation of *Arabidopsis* plants with a recombinant vector comprising either LCAT 1, 2, 3, or 4, (SEQ ID NO: 2, 4, 6 or 8) (pages 44-45 specification); thin layer chromatography assay for cholesterol ester production (i.e. the activity of a lecithin:cholesterol acyltransferase) in insect cells transformed with a baculovirus expression system comprising LCAT1, 2, 3 or 4 (SEQ ID NO: 2, 4, 6 or 8) showing cholesterol ester production in insect cells transformed with a baculovirus expression system comprising LCAT4 SEQ ID NO: 8 (page 47 specification) and increases in phytosterols in seeds of *Arabidopsis* plants transformed with LCAT4 SEQ ID NO: 8 (pages 45 specification); *Arabidopsis* plants transformed with LCAT3 SEQ ID NO: 6 having a 50% increase in esterified sterols in transformed seeds (page 46 of specification, lines 27-30); and *Arabidopsis* plants transformed with LCAT2 SEQ ID NO: 4 having an increase in oil content in transformed seeds (page 46 lines 1-4 and page 49 specification).

Art Unit: 1638

Applicant does not teach baculovirus expression resulting in sterol ester production (i.e. the activity of a lecithin:cholesterol acyltransferase) or phytosterol increases in transformed seeds with any LCAT-like polynucleotide sequence other than LCAT4 (SEQ ID NO: 8); or increases in sterol ester production in seeds transformed with any LCAT-like polynucleotide sequence other than seeds transformed with LCAT3 (SEQ ID NO: 6); or increases in oil production in the seeds transformed with any LCAT-like polynucleotide sequence other than seeds transformed with LCAT2 (SEQ ID NO: 4).

The state-of-the-art is such that one of skill in the art cannot predict which nucleic acids that have at least 70% sequence identity, or hybridize to SEQ ID NO: 4, or have homology to a human lecithin:cholesterol acyltransferase polynucleotide will encode a lecithin:cholesterol acyltransferase-like polypeptide. The inherent unpredictability in isolation of a homologous sequence encoding the same protein activity is illustrated in an example where a small number of changes to the coding region for a strict desaturase resulted in an enzyme with a hydroxylase activity showing that a small number of changes to the coding region of a desaturase could account for the functional divergence seen across a range of enzymes involved in fatty acid metabolism (Broun P. *et al.* Science Vol. 282; 13 November 1998, pp. 1315-1317; Abstract lines 4-6 and p. 1317 column 1, lines 37-56). An example of the unpredictability in isolating lecithin:cholesterol acyltransferase-like encoding polynucleotides using a predictive homology based method is made evident in experiments where 4 gene from *Arabidopsis* were identified by homology based prediction and assumed to encode a putative lecithin:cholesterol acyltransferase but resulted in not one of the four genes being identified as a LCAT encoding gene. Moreover, the gene the authors deemed most likely to encode a lecithin:cholesterol acyltransferase showed

Art Unit: 1638

phospholipase A1 activity when transformed into a yeast mutant resulting in the accumulation of triacylglycerol (TAG) and fatty acids (FA) but no increases in sterol-esters (SE). (Noiriel A. *et al.* European Journal of Biochemistry, 2004; Vol. 271, pages 3752-3764; see Abstract lines 1-7; cloning of LCAT-like cDNAs on page 3753 in column 2; page 37576 column 2 beginning with line 4; and the Discussion beginning on page 3761 to page 3762 column 1 line 4). Further, it appears that Applicant's elected invention drawn to SEQ ID NO: 4 does not produce phytosterols or esterified sterols when assayed *in vitro* or in the seeds of transformed plants.

Given the lack of guidance in the instant specification, undue trial and error experimentation would be required for one of ordinary skill in the art to screen through the multitude of non-exemplified polynucleotide sequences encoding non-exemplified putative lecithin:cholesterol acyltransferase-like polypeptides and fragments thereof, by producing expression vectors to test for activity and product formation and by transforming plants therewith, in order to identify those polynucleotides that when over-expressed or expressed in antisense orientation would produce plants that yield increased phytosterols, increased oil content, or increases in the amount of esterified sterols in their transformed seeds.

Therefore, given the breadth of the claims; the lack of guidance and working examples; the unpredictability in the art; and the state-of-the-art as discussed above, undue experimentation would be required to practice the claimed invention, and therefore the invention is not enabled throughout the broad scope of the claims.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 46-47 and 49-50 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claimed inventions encompass untransformed progeny and seeds, which are a product of nature and not one of the five classes of patentable subject matter. Claims 46-47 and 49-50 are drawn to parts such as seeds or progeny of the transformed plant. Due to Mendelian inheritance of genes, a single gene introduced into a parent plant would only be transferred at most to half the male gametes and half the female gametes. This translates into only two thirds of the progeny having at least a single copy of the transgene and one quarter of the progeny would not carry a copy of the transgene. Since the claim encompasses progeny that lack the transgene, the claim encompasses plants and seeds that are indistinguishable from plants and seeds that would occur in nature. See *American Wood v. Fiber Distintegrating Co.*, 90 U.S. 566 (1974), *American Fruit Growers v. Brogdex Co.*, 283 U.S. 2 (1931), *Funk Brothers Seed Co. v. Kalo Inoculant Co.*, 33 U.S. 127 (1948), *Diamond v. Chakrabarty*, 206 USPQ 193 (1980).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-2, 5-7, 10-11, 22-23, 26, 28, 30, 32, 34, 36, 38, 40 and 41 are rejected under 35 U.S.C. 102(a) as being anticipated by Federspiel N. *et al.* Gene F21M11.5 as GenBank Accession Number AC003027 December 30, 1998 in light of The Institute for Genomic Research database annotation for Gene F21M11.5; see attachment.

Art Unit: 1638

Applicant broadly claims an isolated polynucleotide encoding a plant lecithin:cholesterol acyltransferase-like polypeptide or fragment thereof, wherein the Office interprets lecithin:cholesterol acyltransferase-like to encompass any degree of similarity to any lecithin:cholesterol acyltransferase gene.

Federspiel teaches BAC F21M11, a bacterial cloning vector comprising a cloned segment of *Arabidopsis* chromosome I comprising gene F21M11.5 which encodes a plant lecithin:cholesterol acyltransferase-like polypeptide (see attached TIGR annotation), and that also comprises the plant lecithin:cholesterol acyltransferase-like gene's 5' upstream regulatory promoter sequence and termination sequence (see as GenBank Accession AC003027 and attached sequence reports), and wherein Applicant states for the record on page 31, lines 24-30 of the specification, that SEQ ID NO: 4 encoding SEQ ID NO: 5 is GenBank database accession AC003027, wherein the isolated regulatory sequence comprises a promoter region that is heterologous to the bacterial host cell and is inherently heterologous because it is recombinant, and wherein the isolated 5' upstream regulatory regulatory sequence inherently comprises a combination of constitutive, inducible, developmental or tissue specific promoter expression elements, wherein the 5'X-(R₁)_n-(R₂)_n-(R₃)_n-Y3' formula of Claim 11 having X5' and Y3' as hydrogen is inherently taught by the isolated polynucleotide of the BAC clone in aqueous solution or soluble/hydrated form and wherein the office interprets any nucleic acid of R₁ and R₃ to be a nucleic acid of any length and sequence identity; and wherein a bacterial host cell that comprises the recombinant BAC clone is taught inherently; and thus the reference teaches all the limitations of Claims 1-2, 5-7, 10-11, 22-23, 26, 28, 30, 32, 36, 38, 40 and 41.

All claims are rejected.

Art Unit: 1638

Claims 42-50, 76-78, 82, 84, 86, 88, 107, 108, 111, 113, 115 and 117 are deemed free of the prior art, given the failure of the prior art to teach or reasonably suggest plants transformed with a polynucleotide encoding a lecithin:cholesterol acyltransferase-like polypeptide.

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Russell Kallis whose telephone number is (571) 272-0798. The examiner can normally be reached on M-F 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink that reads "Russell Kallis". The signature is written in a cursive, flowing style.

Russell Kallis Ph.D.
December 10, 2004

qHachement

Best Local Similarity 100.0%; Pred. No. 1.2e-130;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60
DB 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60

QY 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120
DB 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120

QY 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180
DB 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180

QY 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240
DB 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240

QY 241 AAG 243
DB 241 AAG 243

RESULT 4
AX037587
LOCUS AX037587 3896 bp DNA linear PAT 16-NOV-2000
DEFINITION Sequence 11 from Patent WO0060095.
ACCESSION AX037587
VERSION AX037587.1 GI:11227006
KEYWORDS
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 Banas.A., Stahl.U., Stymne.S., Lenman.M., Ronne.H. and Dahlqvist.A.
A new class of enzymes in the biosynthetic pathway for the
production of triacylglycerol and recombinant dna molecules
encoding these enzymes
Patent: WO 0060095-A 11 12-OCT-2000;
BASF PLANT SCIENCE GMBH (DE) ; BANAS ANTONI (PL) ; STAHL ULF (SE) ;
STYMNE STEN (SE) ; LENMAN MARIT (SE) ; RONNE HANS (SE) ; DAHLQVIST
ANDERS (SE)

FEATURES
source 1..3896
/organism="Arabidopsis thaliana"
/mol_type="unassigned DNA"
/db_xref="taxon:3702"

ORIGIN
Query Match 14.8%; Score 243; DB 6; Length 3896;
Best Local Similarity 100.0%; Pred. No. 1.2e-130; Mismatches 0; Indels 0; Gaps 0;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60
DB 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60

QY 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120
DB 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120

QY 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180
DB 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180

QY 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240
DB 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240

QY 241 AAG 243
DB 241 AAG 243

RESULT 6
AX037587
LOCUS AX037587 119914 bp DNA linear PLN 30-OCT-2002
DEFINITION Arabidopsis thaliana chromosome I BAC F21M11 genomic sequence,
complete sequence.
ACCESSION AC003027
VERSION AC003027.1 GI:4079614
KEYWORDS HTG.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 (bases 1 to 119914)
Fedorovskii,N.A., Palm,C.J., Conway,A.B., Conn,L., Hansen,N.F.,
Altati,H., Araujo,R., Huizar,L., Rowley,D., Buehler,E., Dunn,P.,

Db 241 AAG 243

RESULT 5
AX037606
LOCUS AX037606 3896 bp DNA linear PAT 16-NOV-2000
DEFINITION Sequence 30 from Patent WO0060095.
ACCESSION AX037606
VERSION AX037606.1 GI:11227020
KEYWORDS
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 Banas.A., Stahl.U., Stymne.S., Lenman.M., Ronne.H. and Dahlqvist.A.
A new class of enzymes in the biosynthetic pathway for the
production of triacylglycerol and recombinant dna molecules
encoding these enzymes
Patent: WO 0060095-A 30 12-OCT-2000;
BASF PLANT SCIENCE GMBH (DE) ; BANAS ANTONI (PL) ; STAHL ULF (SE) ;
STYMNE STEN (SE) ; LENMAN MARIT (SE) ; RONNE HANS (SE) ; DAHLQVIST
ANDERS (SE)

FEATURES
source 1..3896
/organism="Arabidopsis thaliana"
/mol_type="unassigned DNA"
/db_xref="taxon:3702"

ORIGIN
Query Match 14.8%; Score 243; DB 6; Length 3896;
Best Local Similarity 100.0%; Pred. No. 1.2e-130; Mismatches 0; Indels 0; Gaps 0;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60
DB 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60

QY 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120
DB 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120

QY 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180
DB 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180

QY 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240
DB 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240

QY 241 AAG 243
DB 241 AAG 243

RESULT 6
AX037607
LOCUS AX037607 119914 bp DNA linear PLN 30-OCT-2002
DEFINITION Arabidopsis thaliana chromosome I BAC F21M11 genomic sequence,
complete sequence.
ACCESSION AC003027
VERSION AC003027.1 GI:4079614
KEYWORDS HTG.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 (bases 1 to 119914)
Fedorovskii,N.A., Palm,C.J., Conway,A.B., Conn,L., Hansen,N.F.,
Altati,H., Araujo,R., Huizar,L., Rowley,D., Buehler,E., Dunn,P.,

Db 241 AAG 243

RESULT 5
AX037606
LOCUS AX037606 3896 bp DNA linear PAT 16-NOV-2000
DEFINITION Sequence 30 from Patent WO0060095.
ACCESSION AX037606
VERSION AX037606.1 GI:11227020
KEYWORDS
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 Banas.A., Stahl.U., Stymne.S., Lenman.M., Ronne.H. and Dahlqvist.A.
A new class of enzymes in the biosynthetic pathway for the
production of triacylglycerol and recombinant dna molecules
encoding these enzymes
Patent: WO 0060095-A 30 12-OCT-2000;
BASF PLANT SCIENCE GMBH (DE) ; BANAS ANTONI (PL) ; STAHL ULF (SE) ;
STYMNE STEN (SE) ; LENMAN MARIT (SE) ; RONNE HANS (SE) ; DAHLQVIST
ANDERS (SE)

FEATURES
source 1..3896
/organism="Arabidopsis thaliana"
/mol_type="unassigned DNA"
/db_xref="taxon:3702"

ORIGIN
Query Match 14.8%; Score 243; DB 6; Length 3896;
Best Local Similarity 100.0%; Pred. No. 1.2e-130; Mismatches 0; Indels 0; Gaps 0;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60
DB 1 ATGGGAGCGAATTCGAATCAGTAACGCTTCCCTTACCGTCATCGCGTTCCTTTCTTG 60

QY 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120
DB 61 ATTTCGGTGGCGAATTCGCGTGGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120

QY 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180
DB 121 CTATCGGTATATCAATTCGGGATTCGCTGCGAGCGAGTACGAGCGTGTGATCCTT 180

QY 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240
DB 181 GACTGTCCATACACTCCGTTGAGATTCAATCGCTGCACCTCGTATGCTAGACCACT 240

QY 241 AAG 243
DB 241 AAG 243

RESULT 6
AX037607
LOCUS AX037607 119914 bp DNA linear PLN 30-OCT-2002
DEFINITION Arabidopsis thaliana chromosome I BAC F21M11 genomic sequence,
complete sequence.
ACCESSION AC003027
VERSION AC003027.1 GI:4079614
KEYWORDS HTG.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 (bases 1 to 119914)
Fedorovskii,N.A., Palm,C.J., Conway,A.B., Conn,L., Hansen,N.F.,
Altati,H., Araujo,R., Huizar,L., Rowley,D., Buehler,E., Dunn,P.,

see F21M11.5 on p.3
and TIGR database report

```

/db_xref="GI:4204284"
/translation="WAPNLRIKKACDAMKLLGISETKTRAPLKULLTKYNNWVFTIE
DAYKLLDFAIDFAADQAEQTEKNKSEKKSEERKSRVATSRGRKAPAPLVDDEE
DMVDEDFPLKRLSRGRASSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS
VRNRGRGLAMTYNNASPSRSMSEBEPYPMVLFAHMETTAMDDYVSSASAILND
ENIDHKVISTQSCASPMLEKSNHIVQEWDETKDILNDITAMDDYVSSAIGES
SHKVAASVELASTSGBAKCLGAPATGETTNLHLPMSMEDLRAMEKCKLSKYI
VHPEFVLGFMKDMSCSYDILAKNSQLETTETVCDMSGADSGAVGIMPLVVPV
EUISDGNKAIANNKDIITAGSENVCAIPWMEINEKVPSEFRYMEHSEVFOADPVI
LSQFDEQSCSSCIEDCLASMSNCALGVANGFAYTLDGLLKBEFLSEARQD
RKQVLFCECELEAKKVEILEPCKGHUKRAGEKWEFKCGCTKRCGNRVQVRGMHN
KLQVFTTQKMGWGLTLEKLPKAFIICYEIGLITLPELQAGFTEGTLPLVLLDAH
WGSEERLEGKALCIDGMFYGNISRFNLHGEIDANLIEIPVQETPDQHYHLAFTF
RDTAEAMELAWDYGIDENDNSLMKPFDCLCGRSFCRNKRKSTKTMQILNKA"
13033..14514
/gene="F21M11.2"
join(13033..13488,13717..13926,14139..14514)
/gene="F21M11.2"
join(13061..13488,13717..13926,14139..14316)
/gene="F21M11.2"
/notes="Similar to acid phosphatase; Location of ESTs
110C217, gb|T42036, and 110C237, gb|A1100245"
/codon_start=1
/protein_id="AABD10666.1"
/db_xref="GI:4204285"
/translation="MDRTFSLTIALSLVGVVSGDWNLNQLRGLGSSSSQNGIVS
KGTITLKGVCESRVNVEVHNIRKTVQECVSHIKDYMTSQKDDVARTVDEVI
LHFGSCCKSKCDGMADTDFDITLLSTPIYHKNGFGGKLAFTKPFEDYQKQK
APAVPMWKLHYDIRGKIKTPIFSKRVLSRATVDNLIQAGYGWSNLMRGLGDD
QKEVKQKSEKRWKLSLGVRYGVGWDQSSFAGCPLPRTFKLPNSIYYVA"
complement(14004..16362)
/gene="F21M11.3"
complement(join(14004..14312,14565..14641,14787..15831,
15906..16006,16327..16362))
/gene="F21M11.3"
complement(join(14567..14641,14787..15831,15906..16006,
16327..16362))
/gene="F21M11.3"
/notes="Unknown protein; Location of ESTs 40C3TT,
gb|AAV28590 and 40C317, gb|T04573"
/codon_start=1
/protein_id="AABD10667.1"
/db_xref="GI:4204286"
/translation="MDQISGNTHKLSVETAEPHLNDRVHVEIPKASVPIPTE
TCDQIEAKGCFSTISKRKRVTFDSKVTYHVEVSESEKNEVSEKSLKSSK
IDQIEAENGSGSPENHRYKXNRESDDIEEDFDCSDLDDEEYISDVGSFKE
DSLNPOTVQIIGDKTEIDKLSRNETVDRGNHYDQGVLPVENLTQWKSAG
SKRGTQKQKQKNSPIADQEKRSNSETGPTDQIIDITLSVKPKCRIEPLKRNQ
LAYDASITSLWTSSEKSECNASMTLTPEKLKTSKCYSKPLRINHDDRPVLCAL
EDIKQPSATSTPSPKSKSDEFTPLIGTVGVGWNGRSKALDCGSASSFKGIPNTSSKY
REDKSNVHSTPSPKSKSDEFTPLIGTVGVGWNGRSKALDCGSASSFKGIPNTSSKY"
complement(16835..20238)
/gene="F21M11.4"
complement(join(16835..17185,17274..17392,17491..17656,
17795..17885,17982..18079,18175..18361,18504..18604,
18705..19049,19134..19349,19439..19791,19862..19967,
20188..20238))
/gene="F21M11.4"
/notes="Hypothetical protein"
/codon_start=1
/protein_id="AABD10669.1"
/db_xref="GI:4204288"
/translation="WMSQSPPEARAOVPSMILFLBIIICTVHYVNNRKLNRDLVSA
NLNIPKXVTRDILFMSVTSIYKLSNAVSLHPOLOQIPNDCKNDKLNNSPKX
GESDSMTDKDVKRGGTSSRSDGSPLETSRSPRKHODWTSKQSLDHLLVLE
FESSYDANHTPSTTSQAKNQHVADITASQPSNAARKICGDSFIQESSPNKTOPD
TLLEMSLESRDDPTTQAKNQHVQVYFVWVITVSLRNNLRKLVIFCVQQLPKE
SHTEQDSKREDITASDAMENHLKVPKRNLMQKSDIPCNKCSANSDDQSEKLS
KALPQTSNITICGFCQSVASRGLTGMHLHSGRPVDGDDIFRSNVHVPKAREISRC
POVYEDFLLCPAHSLVARGWKIKCTKCSLKGAAALGCFVKSRCRSHVPCAREISRC
WYEDFLLCPAHSLVARGWKIKCTKCSLKGAAALGCFVKSRCRSHVPCAREISRC
SALSQSKKLWESLAVFNATISYWNPSVTHVIASTDEKGACTRTLKVLGMLNGKWL

```

IIANAMKASLKASQVDEBEPEIQTDTGCGGKTAELRAETNKPKLPEGLKXEF
GDFYKGLDQLNLYKVGAGTILNTEDELGRSSNNVNDQSSSVVTVNIDPFGCAL
GEEVTLIWRANDAEALASQTSRLVGHWTWVLESAGYKLPVIG
20752..24647

gene

CDS
join(20752..20994,21362..21497,21596..21740,21825..21994,
22102..22178,22542..22758,22920..23064,23343..23442,
23499..23693,23821..24072,24227..24298,24441..24647)
/gene="F21M11.5"
/notes="Hydrophobic cal protein"
/codon_start=1
/protein_id="AADI0668.1"
/db_xref="GI:4204287"

translations="MGANSKSVTASFTVIAVFLICGGRTAVEDETERHGYSKLSGI
IIPGASTOLRAWSILDCTVPLDPLDVLDTKLLSAVNCWFKMWDVYNQD
HPCKSRPDSGLSALTDELPGXITGSLVWKWELKWCVEGIEANAVIAYDWRLS
PTKLERDIAHYKGLKLTPTALKLRGSPSIVFAHSGNNVRYFLEWLRLEIAPKXVL
KWLQDRIHFAVGLKLTPTALKLRGSPSIVFAHSGNNVRYFLEWLRLEIAPKXVL
KWLQDRIHFAVGLKLTPTALKLRGSPSIVFAHSGNNVRYFLEWLRLEIAPKXVL
SKCKGNTWTWFSGGAARKKRVYHDEBYQSKYSGWPTNIIINISPTARELA
DGLTFAIEDYDPSKRMHLQKUYVFFVEENIARSLAGFLYHDDPVPFNLTW
ERPPKNTVFCYGAHLKTEVGYFAPSGKFPDNIITDIYETEGSLVSRSRGTVDG
NAGPITGDETPVYHSLSWCKNMLGPKVNTIAPQLIGIKQPEHGDGSDVHVELNVD
HEHGSDFIANTKAPRVKVIITFYDESIPGKRKTAWELDKSGY"
27777..28734
/gene="F21M11.6"
/db_xref="GI:4204289"

translations="MNTKTRLPRLVLTADKKRERDAPISVTPNPEIAKFPSPPP
KLVPVPVNISSKSTAAAPIGSNQIMLAGLSHEYLTQGLFGEQWNAQAQAES
KIKPSHTVEPAECEPKRYREVANLLRSQALPGVIVPAQLARFLKL"
complement(29264..32033)
/gene="F21M11.7"
complement(join(29264..31015,31312..31414,31484..31587,
14.88; Score 243; DB 8; Length 119914;
Query Match 14.88; Score 243; DB 8; Length 119914;
Best Local Similarity 100.0%; Pred. No. 1.1e-130;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGGAGCGAATTCGAAATCAGTAAGCGCTTCCTTCACCGTCATCGCCGTTTTTTCTTG 60
DB 20752 ATGGGAGCGAATTCGAAATCAGTAAGCGCTTCCTTCACCGTCATCGCCGTTTTTTCTTG 20811
QY 61 ATTTGCGGTGCGCAATCGGTGCGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 120
DB 20812 ATTTGCGGTGCGCAATCGGTGCGAGATGAGACCGAGTTTCACGGCGACTACTCGAAG 20871
QY 121 CTATCGGGTATATCATTCGCGGATTTGCGTCACGACGACTACGAGCGGTGTCGATCCTT 180
DB 20872 CTATCGGGTATATCATTCGCGGATTTGCGTCACGACGACTACGAGCGGTGTCGATCCTT 20931
QY 181 GACTGTCCATACATTCGTTGGACTTCAATCCGCTGACCTGCTGCTAGACACCACT 240
DB 20932 GACTGTCCATACATTCGTTGGACTTCAATCCGCTGACCTGCTGCTAGACACCACT 20991
QY 241 AAG 243
DB 20992 AAG 20994

RESULT 7
AX090361
LOCUS
DEFINITION
*ACCESSION
VERSION
KEYWORDS

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

AX090361
Sequence 54 from Patent WO0116308.
AX090361
AX090361.1 GI:13444222

SOURCE
ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

source

1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

ORIGIN

Query Match 1.6%; Score 27; DB 6; Length 44;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGGAGCGAATTCGAAATCAGTAACG 27
DB 18 ATGGGAGCGAATTCGAAATCAGTAACG 44

RESULT 8
AX090362/c
LOCUS

DEFINITION
ACCESSION
VERSION
KEYWORDS

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

AX090362
Sequence 55 from Patent WO0116308.
AX090362
AX090362.1 GI:13444223

synthetic construct
synthetic construct
artificial sequences.

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"

1
Lasser, M. and van Benennaam, A.
AUTHORS
Plant sterol acyltransferases
Patent: WO 0116308-A 54 08-MAR-2001;
MONGSANTO COMPANY (US)
LOCATION/Qualifiers
1.44
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide primer"